Today ABG Sundal Collier sponsored research initiates coverage of Herantis Pharma. Read the full report (61 pages) here!
Herantis Pharma - Novel treatments for Parkinson’s and BCAL
Herantis Pharma is a publicly listed (Finland, HRTIS and Sweden, HRNTS) drug development company aiming to revolutionize the treatment of diseases with unmet clinical needs. Based on leading academic research published in high-impact journals including Nature and Science, two ongoing clinical development programs explore the potential of its novel drug candidates in Parkinson’s disease and secondary lymphedema. Both Parkinson’s disease and lymphedema remain conditions in which current treatments only address symptoms and therefore do not enable long-term improvement for patients.